Check for updates

OPEN ACCESS

EDITED BY Lorie Gage Richards, The University of Utah, United States

REVIEWED BY Ljubica Konstantinovic, University of Belgrade, Serbia Mostafa Meshref, Al-Azhar University, Egypt

*CORRESPONDENCE Zhenyu Wang 🖾 804791727@qq.com; 🖾 wangzhenyudr@163.com

RECEIVED 14 July 2024 ACCEPTED 14 October 2024 PUBLISHED 07 November 2024

CITATION

Ke W, Cheng H, Ren X, Yang L, Lai X and Wang Z (2024) Efficacy of acupuncture combined with mirror therapy in the treatment of post-stroke limb movement disorders: a systematic review and meta-analysis of randomised controlled trials. Front. Rehabil. Sci. 5:1464502. doi: 10.3389/fresc.2024.1464502

COPYRIGHT

these terms

© 2024 Ke, Cheng, Ren, Yang, Lai and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with Efficacy of acupuncture combined with mirror therapy in the treatment of post-stroke limb movement disorders: a systematic review and metaanalysis of randomised controlled trials

Weihao Ke¹, Hongxin Cheng¹, Xiaoxuan Ren², Liang Yang¹, Xiaomin Lai¹ and Zhenyu Wang³*

¹Department of Rehabilitation Medicine, The Affiliated Yong Chuan Hospital of Chong Qing Medical University, Chongqing, China, ²Sichuan Province Orthopaedic Hospital, Department of Neck, Shoulder, Back, and Leg Pain, Wuhou District, Chengdu, China, ³The Affiliated Rehabilitation Hospital of Chong Qing Medical University, Administrative Department, Jiulongpo District, Chongqing, China

Objective: To investigate whether the combination of acupuncture and mirror therapy can improve motor impairment in stroke patients.

Design: A systematic review and meta-analysis of randomised controlled trials. **Data sources:** CNKI, Wanfang, PubMed, Embase, Vip, web of since, Cochrane database and CBM database.

Eligibility criteria for selecting studies: The included randomized controlled trials compared the efficacy of acupuncture therapy (AT) combined with mirror therapy (MT) against AT, MT, and conventional rehabilitation therapy on limb motor impairment in stroke patients, with independent data extraction and study quality assessment conducted. A META analysis using fixed-effect and random-effect models was performed to calculate the mean difference (MD) in motor scores and the Total effective rate RR (Risk ratio) between the AT combined with MT group and the control group.

Main outcome measures: The Fugl-Meyer Assessment (FMA) for motor function includes the FMA-T (total FMA), FMA-UE (upper extremity FMA), and FMA-L (lower extremity FMA).

Results: A total of 42 randomized controlled trials were included, involving 3,340 patients with post-stroke motor impairment. AT combined with MT was more favorable for FMA-UE (mean difference [MD] = 6.67, 95% CI [5.60–7.93], Z = 11.42, P < 0.0001), FMA-L [MD = 3.37, 95% CI (2.99–3.76), Z = 17.31, P < 0.001], and FMA-T [MD = 6.84, 95% CI (5.92–7.77), Z = 14.48, P < 0.001]. The combined AT and MT treatment was more favorable for the Modified Barthel Index (MBI) score in post-stroke motor impairment [MD = 10.82, 95% CI (8.52–13.12), Z = 9.22, P < 0.001]. AT combined with MT was more favorable for the Modified For the Modified Ashworth Scale (MAS) [MD = -0.34, 95% CI (-0.66 to -0.03), Z = 14.48, P < 0.001]. AT combined with MT was more favorable for the Total effective rate in treating post-stroke motor impairment (relative risk = 1.27, 95% confidence interval [CI] [1.19–1.37], Z = 6.54, P < 0.001].

Conclusions: AT combined with MT can effectively improve patients' motor function and daily living abilities.

Systematic Review Registration: PROSPERO, identifier, CRD42024559992.

KEYWORDS

acupuncture, mirror therapy, stroke, motor impairment, meta-analysis

Introduction

Stroke is a globally prevalent and very dangerous disease, with more than 15 million new cases each year. More than 60% of stroke patients face varying degrees of physical disability after the onset of the disease. When cardiovascular disease is considered alone, stroke is the fifth most lethal disease after heart disease, cancer, COVID-19, and unintentional injuries (1). As an outcome of stroke, numerous patients endure long-term motor deficits that can range from unilateral to bilateral paralysis (2–4). Additionally, it can significantly impair their cognitive, memory, speech, respiration, vision, and motor functions. The daily quality of life of stroke victims is significantly impacted by the loss of limb movement ability. Consequently, it is imperative to implement a vigorous approach to the treatment of limb movement disorders in order to facilitate the reintegration of patients into a typical lifestyle and alleviate the burden on their families.

Mostly, traditional non-invasive stroke treatments consist of physiotherapy and pharmacological therapies. Traditional physiotherapy techniques include active and passive movement therapy, balance and gait training, fine motor skill development, physical factor therapy, and occupational therapy (5, 6). Pharmacological treatments often involve anticoagulants, antiplatelet agents, lipid-lowering drugs, and medications that enhance microcirculation (7). However, traditional physiotherapy methods often show limited effectiveness, and pharmacological treatments may cause various side effects. Given these limitations, there is an urgent need to explore innovative physiotherapy approaches to improve treatment efficacy and the quality of life for stroke patients.

Commonly used non-invasive stroke treatment options include physiotherapy and medicines. The physiotherapy interventions mentioned here, although not universally standardized, include active and passive movement therapy, balance and gait training, fine motor skill development, physical factor therapy, and occupational therapy (5, 6). These usually include anticoagulants, antiplatelet medicines, lipid-lowering medications, and pharmaceuticals that increase microcirculation (7). However, these traditional physical therapy methods usually have limited effectiveness. In addition, pharmacological treatments may lead to various side effects. In view of these limitations, there is an urgent need to explore innovative physiotherapy approaches to enhance treatment efficacy and improve the quality of life of stroke patients.

Acupuncture therapy (AT) is a traditional Chinese medicine treatment that works by stimulating specific points on the body to improve the flow of energy and blood. This stimulation helps increase blood circulation to the brain and supports the brain's ability to recover and adapt by promoting changes in its structure and function (known as neuroplasticity). The World Health Organization (WHO) recognizes the importance of AT in stroke rehabilitation (8, 9). In addition, the National Institute for Health and Clinical Excellence (UK) has acknowledged mirror therapy (MT) as a supplementary treatment for post-stroke movement problems (6, 10, 11). Recent studies (12) have emphasized the notable impact of integrating AT treatment with MT. However, current systematic review (13) have certain drawbacks, notably in regards to subgroup analyses of specific AT techniques, treatment length, and disease stage. The objective of this meta-analysis was to methodically evaluate the impact of integrating AT with MT on movement impairments following a stroke. The purpose was to enhance and improve rehabilitation treatment approaches in clinical practice.

Methods

Protocol and guidance

The Reporting Specification for Systematic Evaluation/Meta-Analysis (PRISMA) (14) guided the conduct of this study, and PROSPERO has registered the protocol for this review (CRD42024559992).

Inclusion criteria

We considered trials to be eligible. If trials enrolled stroke patients with movement disorders (age ≥ 18) diagnosed according to any recognized diagnostic criteria, if there were any randomized controlled trials or clinical trials evaluating the efficacy of AT combined with MT for patients diagnosed with upper or lower limb dysfunction, if the studies included at least one of the following parameters as outcome variables: limb

Abbreviations

AT, acupuncture therapy; MT, mirror therapy; FMA-T, Fugl-meyer assessment—total; FMA-UE, Fugl-Meyer assessment—upper extremity; FMA-L, Fugl-Meyer assessment—lower extremity; MBI, modified barthel index; MAS, modified ashworth scale; SA, scalp acupuncture; BA, body acupuncture; OP, other period; SP, subacute period.

motor ability, degree of muscle spasm, clinical efficacy, and ability in daily life activities; if the intervention was AT + MT and the control group was monotherapy, such as AT or MT or conventional rehabilitation.

Exclusion criteria

We excluded studies if they were case reports, *in vivo* animal studies, reviews, or interviews; if they were registered without any outcome data or if data were missing and we were unable to contact the original authors to obtain the relevant outcome data; if they were randomized controlled trials assessing only the efficacy of AT alone or MT alone in stroke patients; if the study content did not have relevant outcome variables.

Outcomes

The primary outcome measures were FMA-T, FMA-UE, and FMA-L. Modified MAS, MBI, and Total effective rate served as the secondary outcome measures. Supplementary eTable S1 shows the definitions of these outcomes.

Search strategy

One of the authors (XX Ren) searched the following databases: the CNKI, Wanfang, PubMed, Embase, Vip, Web of Since, and the Cochrane database and CBM database. We did not restrict the language. The search was conducted from the beginning until July 3, 2024. Supplementary eTable S2 describes the search strategy.

Study selection

After removing duplicates, two independent researchers (L Y and XM Lai) screened all titles and abstracts. They were provided with the full text and carried out further screening when deemed eligible.

Data collection process

Two independent researchers (L Y and XM Lai) extracted data from the included trials using standard data extraction forms. If a randomized controlled trial had more than two treatment groups, we pooled data from the different treatment groups. If a study mentioned an outcome of interest but did not provide an estimate, we contacted the authors to obtain the data. If there were disagreements, we resolved them by consensus.

Assessment of risk of bias and quality of evidence

The quality of eligible studies was independently assessed by two reviewers (HX Chen, WH Ke) using the Cochrane Collaboration Risk of Bias Tool (15, 16), and in case of disagreement, it was discussed and resolved with a third reviewer (XX Ren).

Data synthesis

Meta-analysis was performed using RevMan 5.3 and Stata 16.0 software. Mean difference (MD) was used as the effect size (effect size) for continuous outcome indicators, and RR (risk ratio) was used as the effect size for dichotomous variables. The Q test and I statistic were used to examine inter-study heterogeneity; if P > 0.1 or $I^2 < 50\%$, it meant that there was no heterogeneity between studies and a fixed-effects combined effect size was needed, and vice versa, a random-effects combined effect size was used. Further, the possibility of publication bias was assessed qualitatively by visual estimation of the funnel plot and quantitatively by calculation of the Egger test (17).

Subgroup analyses

We conducted subgroup analyses to test for interactions based on the duration of treatment (≤ 4 weeks, ≥ 6 weeks), type of AT (Scalp Acupuncture, body acupuncture), and stage of disease (Other Period,Subacute Period).

Sensitivity analyses

We conducted sensitivity analyses to confirm the stability and credibility of the results of this meta-analysis using the Leave-One-Out method, which means omitting each study individually to exclude all factors that could have a significant impact on the pooled effect.

Results

Eligible studies and study characteristics

After first screening 263 records, our final meta-analysis (shown in Figure 1) included 42 suitable trials (12, 18–58). Together, these investigations included 3,340 people ranging in age from 50 to 80 years. While the control groups received MT, AT, or rehabilitation therapy (RT) alone, with treatment durations ranging from a minimum of 2 weeks to a maximum of 12 weeks, the intervention groups received both MT and AT. Supplementary Spreadsheets 3, 4 contain further information on these studies; Supplementary eTables 1, 2 evaluate the risk of bias across the trials. Only one study was found to be highly biassed; the other studies showed low to moderate hazards, implying a largely consistent body of evidence.

Primary outcome: FMA

Data on FMA-T, FMA-UE, and FMA-L were reported in 4, 23, and 10 trials, respectively. FMA-T, FMA-UE, and FMA-L were



higher in the intervention group than in the control group by 6.84 (95% CI 5.92–7.77, $I^2 = 20\%$; Figure 2), 6.77 (95% CI 5.60–7.93, $I^2 = 87\%$; Figure 3), and 3.37 (95% CI 2.99–3.76, $I^2 = 41\%$; Figure 4), respectively. Among them, Egger's test of FMA-T (P = 0.1285) did not find the existence of publication bias (Supplementary eFigure S3). The Egger's test of FMA-UE and FMA-L (P < 0.05) found the existence of publication bias; then the cut-and-patch method was needed, and after the cut-and-patch, it was found that the combined effect sizes of FMA-UE and FMA-L were not significantly changed, implying that there was a slight publication bias. change, implying the existence of a

slight publication bias, which does not affect the stability of the study results (Supplementary eFigures 4, 5). In sensitivity analyses, the results of meta-analyses of FMA-T, FMA-UE, and FMA-L were robust (Supplementary eFigures 6–S8).

Subgroup analyses found that the efficacy of FMA-L for ≥ 6 weeks of treatment was significantly higher than that for ≤ 4 weeks of treatment (interaction P = 0.02; Figure 5), and the efficacy was significant regardless of whether it was ≤ 4 weeks or ≥ 6 weeks; subgroup analyses found that there was no significant difference in the efficacy of FMA-UE for ≥ 6 weeks of treatment compared with that for ≤ 4 weeks of treatment (interaction



	A	T+MT		Mone	othera	ру		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
Aijun Wang 2022	25.33	5.07	54	22.57	6.62	54	3.0%	2.76 [0.54, 4.98]	
Di Zhu 2019	26.6	3.7	40	22.45	4.09	80	6.9%	4.15 [2.69, 5.61]	
Keyong Cao 2022	25.04	4.69	27	19.74	3.73	54	3.5%	5.30 [3.27, 7.33]	
Lixia Chen 2021	27.63	2.52	42	22.63	4.82	42	5.4%	5.00 [3.36, 6.64]	
Lixia Chen 2022	29.26	4.23	50	25.78	3.81	50	5.9%	3.48 [1.90, 5.06]	
Mingzhu Xu 2023	24.3	1.3	28	21.05	0.97	58	49.6%	3.25 [2.71, 3.79]	_
Qin Yang 2020	27.39	2.43	30	25.25	2.32	30	10.1%	2.14 [0.94, 3.34]	
Shaoyang Cui 2017	22.37	4.83	33	17.64	4.65	32	2.7%	4.73 [2.43, 7.03]	
Xiaoli Song 2024	25.48	5.04	40	21.75	4.53	40	3.3%	3.73 [1.63, 5.83]	
Xiuhua Zhang 2018	22.39	3.27	60	19.65	3.61	60	9.6%	2.74 [1.51, 3.97]	
Total (95% CI)			404			500	100.0%	3.37 [2.99, 3.76]	•
Heterogeneity: Chi ² =	15.32, di	f = 9 (F	e = 0.08	(); $l^2 = 4^{\circ}$	1%			-	
Test for overall effect:	Z = 17.3	1 (P <	0.0000	1)					-4 -2 U 2 4 Favours (Monotherapy) Favours (AT+MT)
GURE 3									
prest plot of FMA-UE				A.T	AT				

P = 0.63; Figure 6), and the efficacy of FMA-UE for either ≤4 or ≥6 weeks was significant. was significant; subgroup analyses revealed no significant difference in FMA-UE and FMA-L efficacy between Scalp Acupuncture(SA) and Body Acupuncture(BA) (interaction $P_{FMA-UE} = 0.22$, $P_{FMA-L} = 0.1$; Figures 7, 8); subgroup analyses found no significant difference in FMA-L, FMA-UE between OP(Other Period) and SA (interaction $P_{FMA-L} = 0.38$, $P_{FMA-UE} = 0.20$, Figures 9, 10), which was significant regardless of OP or SP(Subacute Period).

Secondary outcome: MBI, MAS, and total effective rate

Data on MBI, MAS, and total effective rate were reported in 24, 8, and 8 trials, respectively. The MBI, MAS, and total effective rate were higher in the intervention group than in the control group by 10.82 (95% CI 8.52–13.12, $I^2 = 94\%$; Figure 11), -0.34 (95% CI -0.66–0.03, $I^2 = 97\%$; Figure 12), 1.29 (95% CI 1.20–1.40, $I^2 = 0\%$; Figure 13). Among them, the theorem's test for MBI, MAS, and total effective rate (P_{MBI} = 0.7759, P_{MAS} = 0.9443, and P_{Total effective rate} = 0.2203) did not reveal the presence of publication bias (Supplementary eFigures S9–S11). In the sensitivity analyses, the meta-analysis results of MBI, MAS, and total effective rate were robust (Supplementary Figures 12–S14).

There was no significant difference between the groups in how well MBI worked for MAS upper limb portion of ≥ 6 weeks vs. ≤ 4 weeks (interaction P_{MBI} = 0.69, P_{MAS} upper limb portion = 0.25; Figures 14, 15), and it was effective no matter what time period was used. There was also no significant difference between the groups in how well MBI worked for SA vs. BA (interaction P = 0.70; Figure 16), and it was effective no matter which group it was in. There was also no significant difference between the groups in how well it worked for OP and SP (P_{MBI} = 0.72, P_{Total effective rate} = 0.72, Figures 17, 18), and it was effective no matter which group it was in.

Discussion

In this meta-analysis of 42 randomized controlled trials with a total of 3,440 participants, the results showed that AT combined with MT for the treatment of post-stroke limb dyskinesia resulted in a significantly higher Total effective rate compared to the control group (RR 1.29, 95% confidence interval 1.20–1.40); a significant improvement in FMA-T compared to control (MD 6.84,

		T+MT		Mon	othera			Mean Difference	Mean Difference
Study or Subgroup	Mean		Total	Mean				IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
2.2.1 Course of treat				Wear	30	Total	weight	W, HACU, 5570 CI	N, TIXEU, 35% CI
Mingzhu Xu 2023	24.3	1.3		21.05	N 97	58	49.6%	3.25 [2.71, 3.79]	
Qin Yang 2020	27.39		30			30	10.1%	2.14 [0.94, 3.34]	
Shaoyang Cui 2017	22.37			17.64		32	2.7%	4.73 [2.43, 7.03]	
Xiuhua Zhang 2018	22.39			19.65		60	9.6%	2.74 [1.51, 3.97]	
Subtotal (95% CI)	22.00	0.21	151		0.01	180	72.1%	3.08 [2.63, 3.53]	•
Heterogeneity: Chi ² =	4.99. df=	= 3 (P =	= 0.17)	$ ^{2} = 40^{\circ}$	%				
Test for overall effect:									
2.2.2 Course of treat	ment (>)	6 week	(S)						
Aijun Wang 2022	25.33			22.57	6 62	54	3.0%	2.76 [0.54, 4.98]	
Di Zhu 2019	25.55	3.7	40			80	6.9%	4.15 [2.69, 5.61]	
Kevong Cao 2022	25.04			19.74		54	3.5%	5.30 [3.27, 7.33]	
Lixia Chen 2021	27.63			22.63		42	5.4%	5.00 [3.36, 6.64]	
Lixia Chen 2022	29.26			25.78		50	5.9%	3.48 [1.90, 5.06]	
Xiaoli Song 2024	25.48		40			40	3.3%	3.73 [1.63, 5.83]	
Subtotal (95% CI)	20.10	0.01	253	2		320	27.9%	4.12 [3.40, 4.85]	•
Heterogeneity: Chi ² =	4.60, df=	= 5 (P =	= 0.47)	: I ² = 0%	,				
Test for overall effect:		•		-					
Total (95% CI)			404			500	100.0%	3.37 [2.99, 3.76]	•
Heterogeneity: Chi ² =	15.32. di	f = 9 (P	= 0.08	$0; ^2 = 4^{\circ}$	1%				<u> </u>
Test for overall effect:	•								-4 -2 0 2 4 Favours (Monotherapy) Favours (AT+MT)
Test for subgroup diff				· ·	= 0.02	2), I ² = 8	32.6%		ravours (Monotherapy) ravours (AT+MT)
GURE 4									
prest plot of FMA-L o	utcomes	comp	baring	AT + MT	r with	contro	l interver	ntions.	
,		1	5						

~		AT+MT			otherap	-		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD		Mean			-	IV, Random, 95% Cl	IV, Random, 95% Cl
Can Duan 2020	35.06	11.88	49	30.11	11.63	47	3.0%	4.95 [0.25, 9.65]	
Daojin Xia 2021	41.5	6.8	24	31.6	6.04	24	3.7%	9.90 [6.26, 13.54]	
Han Liu 2019	46.17	3.86	38	38.49	2.15	38	5.4%	7.68 [6.28, 9.08]	
Hangfan Zhou 2017	34.97	7.85	20		8.78	40	3.2%	11.09 [6.70, 15.48]	
Jianming Li 2022	28.32	5.64	47	17.62	5.14	47	4.8%	10.70 [8.52, 12.88]	
Jingjun Xie 2018	45.96	4.03	45	38.58	1.98	45	5.4%	7.38 [6.07, 8.69]	
Jinjing Zhang 2024	26.23	1.77	30	21.92	2.74	60	5.6%	4.31 [3.37, 5.25]	-
Meng Wang 2023	29.58	13.79	31	21.52	12.81	31	2.0%	8.06 [1.43, 14.69]	
Ning Xu 2021	40.73	4.91	38	34.82	4.44	38	4.9%	5.91 [3.81, 8.01]	
Ning Zhang 2021	44.21	2.6	32	40.85	3.2	32	5.4%	3.36 [1.93, 4.79]	
Pingping Gou 2023	42.23	8.76	38	31.84	6.09	38	3.9%	10.39 [7.00, 13.78]	
Qiang He 2023	55.6	6.45	55	44.86	4.4	55	4.9%	10.74 [8.68, 12.80]	
Qiong Luo 2020	28.05	3.81	48	25.72	3.54	48	5.3%	2.33 [0.86, 3.80]	
Rui Zhang 2017	47.7	9.71	20	29.8	9.68	40	2.7%	17.90 [12.69, 23.11]	
Shaoyang Cui 2015	31.66	4.64	32	26.75	4.73	32	4.8%	4.91 [2.61, 7.21]	
Su Zheng 2018	37.5	1.8	30	33.5	1.59	60	5.7%	4.00 [3.24, 4.76]	+
Weidong Yang 2019	42.32	7.67	30	36.34	0.95	30	4.4%	5.98 [3.21, 8.75]	
Kiaoli Song 2024	39.6	8.72	40	32.63	7.25	40	3.8%	6.97 [3.46, 10.48]	
Kinting Wang 2021	35.93	3.5	30	31.1	5.03	60	5.1%	4.83 [3.04, 6.62]	
Kiping Zhang 2018	50.9	8	31	42	7.9	31	3.5%	8.90 [4.94, 12.86]	
Yanan Zhang 2021	34.51	6.62	43	30.81	5.93	43	4.5%	3.70 [1.04, 6.36]	 → −
Zhenglu Yin 2020	40.75	7.18	51	32.54	7.36	25	3.8%	8.21 [4.72, 11.70]	
Zhenyu Ma 2019	31.13	6.54	20	28.23	3.23	20	4.1%	2.90 [-0.30, 6.10]	<u> </u>
Fotal (95% CI)			822			924	100.0%	6.77 [5.60, 7.93]	•
Heterogeneity: Tau² = Test for overall effect: :					< 0.000	01); I² =	87%		-20 -10 0 10 20 Favours (Monotherapy) Favours (AT+MT)

	P	T+MT		Mon	otherap	у		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
3.3.1 SA									
Jianming Li 2022	28.32	5.64	47	17.62	5.14	47	4.8%	10.70 [8.52, 12.88]	
Jingjun Xie 2018	45.96	4.03	45	38.58	1.98	45	5.4%	7.38 [6.07, 8.69]	
Rui Zhang 2017	47.7	9.71	20	29.8	9.68	40	2.7%	17.90 [12.69, 23.11]	
Xinting Wang 2021	35.93	3.5	30	31.1	5.03	60	5.1%	4.83 [3.04, 6.62]	
Zhenglu Yin 2020	40.75	7.18	51	32.54	7.36	25	3.8%	8.21 [4.72, 11.70]	
Zhenyu Ma 2019	31.13	6.54	20	28.23	3.23	20	4.1%	2.90 [-0.30, 6.10]	
Subtotal (95% CI)			213			237	26.0 %	8.16 [5.40, 10.92]	•
Heterogeneity: Tau ² =	9.69; Ch	i ² = 40.1	5, df =	5 (P < 0	.00001)	; I ² = 88	3%		
Test for overall effect: .	Z= 5.79	(P < 0.0	0001)						
3.3.2 BA									
Can Duan 2020	35.06	11.88	49	30.11	11.63	47	3.0%	4.95 [0.25, 9.65]	
Daojin Xia 2021	41.5	6.8	24	31.6	6.04	24	3.7%	9.90 [6.26, 13.54]	
Han Liu 2019	46.17	3.86	38		2.15	38	5.4%	7.68 [6.28, 9.08]	
Hangfan Zhou 2017	34.97	7.85	20		8.78	40	3.2%	11.09 [6.70, 15.48]	
Jinjing Zhang 2024	26.23	1.77		21.92	2.74	60	5.6%	4.31 [3.37, 5.25]	-
Meng Wang 2023		13.79		21.52		31	2.0%	8.06 [1.43, 14.69]	
Ning Xu 2021	40.73	4.91	38		4.44	38	4.9%	5.91 [3.81, 8.01]	
Ning Zhang 2021	44.21	2.6		40.85	3.2	32	5.4%	3.36 [1.93, 4.79]	
Pingping Gou 2023	42.23	8.76		31.84	6.09	38	3.9%	10.39 [7.00, 13.78]	
Qiang He 2023	55.6	6.45		44.86	4.4	55	4.9%	10.74 [8.68, 12.80]	
Qiong Luo 2020	28.05	3.81		25.72	3.54	48	5.3%	2.33 [0.86, 3.80]	
Shaoyang Cui 2015	31.66	4.64		26.75	4.73	32	4.8%	4.91 [2.61, 7.21]	
Su Zhena 2018	37.5	1.8	30	33.5	1.59	60	5.7%	4.00 [3.24, 4.76]	+
Weidong Yang 2019	42.32	7.67		36.34	0.95	30	4.4%	5.98 [3.21, 8.75]	
Xiaoli Song 2024	39.6	8.72	40	32.63	7.25	40	3.8%	6.97 [3.46, 10.48]	
Xiping Zhang 2018	50.9	8	31	42	7.9	31	3.5%	8.90 [4.94, 12.86]	
Yanan Zhang 2021	34.51	6.62	43	30.81	5.93	43	4.5%	3.70 [1.04, 6.36]	
Subtotal (95% CI)	•• .		609			687	74.0%	6.27 [5.04, 7.50]	•
Heterogeneity: Tau ² =	4.71: Ch	i ² = 102	.10. df:	= 16 (P	< 0.0000	01): I ² =	84%	- / -	
Test for overall effect: .						.,,,,			
Total (95% CI)			822			924	100.0%	6.77 [5.60, 7.93]	•
Heterogeneity: Tau ² =	6.01; Ch	i ² = 164	.63, df :	= 22 (P	< 0.0000	01); I ² =	87%		-20 -10 0 10 20
Test for overall effect: .									
Test for subgroup diffe					0.22), F	² = 33.2	2%		Favours [Monotherapy] Favours [AT+MT]
							-		
URE 6									
		t durati							

	A	T+MT		Mone	othera	ру		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Can Duan 2020	1.12	0.54	49	1.36	0.66	47	12.8%	-0.24 [-0.48, 0.00]	
lianming Li 2022	0.81	0.25	47	1.27	0.31	47	13.6%	-0.46 [-0.57, -0.35]	
ixia Chen 2022	1.23	0.19	50	1.31	0.23	50	13.7%	-0.08 [-0.16, 0.00]	
Ruili Wen 2024	0.99	0.14	36	1.96	0.22	36	13.7%	-0.97 [-1.06, -0.88]	
(iaoli Song 2024	1.06	0.87	40	1.41	0.87	40	11.5%	-0.35 [-0.73, 0.03]	
anan Zhang 2021	1.21	0.42	43	1.37	0.35	43	13.3%	-0.16 [-0.32, 0.00]	
Thenglu Yin 2020	0.85	0.35	51	0.88	0.51	25	13.0%	-0.03 [-0.25, 0.19]	
Chenyu Ma 2019	1.63	0.28	20	2.13	1.54	20	8.4%	-0.50 [-1.19, 0.19]	
fotal (95% CI)			336			308	100.0%	-0.34 [-0.66, -0.03]	
Heterogeneity: Tau² =	= 0.19; C	hi² = 2	48.91,	df = 7 (P	× 0.0	0001);1	²= 97%		-1 -0.5 0 0.5 1
Fest for overall effect	: Z = 2.14	(P = ().03)						Favours (AT+MT) Favours (Monotherapy)
URE 7									
ogroup analysis of A	AT type (SA vs.	BA) or	n FMA-I	UE ou	tcome	S.		

95% confidence interval 5.92–7.77); a significant improvement in FMA-UE compared to control (MD 6.77, 95% confidence interval 5.60–7.93); FMA-L was significantly better than control (MD 3.37, 95% confidence interval 2.99–3.76); MBI was significantly improved (MD 10.82, 95% confidence interval 8.52–13.12), and MAS was significantly improved (MD –0.34, 95% confidence interval –0.66 t –0.03) compared with the control group.

Principal findings and comparison with other studies

The findings of this study, which examined the use of AT paired with MT for treating motor deficits after a stroke, indicate that the overall results are not significantly different from those reported in a prior systematic review. Our study

		\T+MT			otherap	-		Mean Difference	Mean Difference
Study or Subgroup	Mean			Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
3.2.1 Course of treat									
Can Duan 2020		11.88	49		11.63	47	3.0%	4.95 [0.25, 9.65]	
Daojin Xia 2021	41.5	6.8	24	31.6	6.04	24	3.7%	9.90 [6.26, 13.54]	
Han Liu 2019	46.17	3.86	38		2.15	38	5.4%	7.68 [6.28, 9.08]	
Jingjun Xie 2018	45.96	4.03		38.58	1.98	45	5.4%	7.38 [6.07, 8.69]	
Jinjing Zhang 2024	26.23	1.77		21.92	2.74	60	5.6%	4.31 [3.37, 5.25]	-
Meng Wang 2023		13.79	31			31	2.0%	8.06 [1.43, 14.69]	
Ning Xu 2021	40.73	4.91		34.82	4.44	38	4.9%	5.91 [3.81, 8.01]	
Pingping Gou 2023	42.23	8.76		31.84	6.09	38	3.9%	10.39 [7.00, 13.78]	
Qiang He 2023	55.6	6.45		44.86	4.4	55	4.9%	10.74 [8.68, 12.80]	
Qiong Luo 2020	28.05	3.81		25.72	3.54	48	5.3%	2.33 [0.86, 3.80]	
Rui Zhang 2017	47.7	9.71	20	29.8	9.68	40		17.90 [12.69, 23.11]	
Shaoyang Cui 2015	31.66	4.64		26.75	4.73	32	4.8%	4.91 [2.61, 7.21]	-
Weidong Yang 2019	42.32	7.67	30		0.95	30	4.4%	5.98 [3.21, 8.75]	
Kinting Wang 2021	35.93	3.5	30	31.1	5.03	60	5.1%	4.83 [3.04, 6.62]	
Yanan Zhang 2021	34.51	6.62	43		5.93	43	4.5%	3.70 [1.04, 6.36]	
Zhenyu Ma 2019	31.13	6.54	20	28.23	3.23	20	4.1%	2.90 [-0.30, 6.10]	
Subtotal (95% CI)			571			649	69.8%	6.60 [5.18, 8.02]	•
Heterogeneity: Tau² =				= 15 (P	< 0.000	01); I ² =	86%		
Test for overall effect:	Z = 9.09	(P < 0.0	0001)						
3.2.2 Course of treat	ment (>f	weeks	`						
Hangfan Zhou 2017	34.97	7.85		23.88	8.78	40	3.2%	11.09 [6.70, 15.48]	
Jianming Li 2022	28.32	5.64		17.62	5.14	47	4.8%	10.70 [8.52, 12.88]	
Ning Zhang 2021	44.21	2.6		40.85	3.2	32	5.4%	3.36 [1.93, 4.79]	
Su Zheng 2018	37.5	1.8	30	33.5	1.59	60	5.7%	4.00 [3.24, 4.76]	+
Kiaoli Song 2024	39.6	8.72	40		7.25	40	3.8%	6.97 [3.46, 10.48]	
Kiping Zhang 2018	50.9	8	31	42	7.9	31	3.5%	8.90 [4.94, 12.86]	
Zhenalu Yin 2020	40.75	7.18	51	32.54	7.36	25	3.8%	8.21 [4.72, 11.70]	
Subtotal (95% CI)	40.10	1.10	251	02.04	1.00	275	30.2%	7.28 [4.88, 9.67]	•
Heterogeneity: Tau ² =	8.26: Ch	i ² = 53.3	86.df=	6 (P < 0	00001	$ ^{2} = 8!$	9%		-
Test for overall effect:				0, 0					
			022			024	400.0%	6 77 15 60 7 001	
Fotal (95% CI)			822				100.0%	6.77 [5.60, 7.93]	
Heterogeneity: Tau² =					< 0.000	U1); l² =	87%		-20 -10 0 10 20
Test for overall effect:		·							Favours (Monotherapy) Favours (AT+MT)
	erences:	Chi ² = (1.23, df	= 1 (P =	: U.63), I	*=0%			· ··· · ·
Test for subgroup diff									
URE 8 bgroup analysis of <i>A</i>									

	AT+N		Monothe	гару		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Jingjun Xie 2018	40	45	31	45	13.8%	1.29 [1.03, 1.61]	
Jinjing Zhang 2024	29	30	21	30	9.3%	1.38 [1.08, 1.76]	
Lixia Chen 2022	48	50	36	50	16.0%	1.33 [1.11, 1.60]	
Ning Xu 2021	32	38	23	38	10.2%	1.39 [1.04, 1.86]	
Ning Zhang 2021	26	32	19	32	8.4%	1.37 [0.98, 1.91]	
Qiong Luo 2020	46	48	39	48	17.3%	1.18 [1.02, 1.37]	
Weidong Yang 2019	29	30	23	30	10.2%	1.26 [1.02, 1.55]	
Yanan Zhang 2020	41	43	33	43	14.7%	1.24 [1.04, 1.48]	
Total (95% CI)		316		316	100.0%	1.29 [1.20, 1.40]	•
Total events	291		225				
Heterogeneity: Chi ² = 3	2.48, df = 7	7 (P = 0	.93); I ^z = 0	%		-	0.7 0.85 1 1.2 1.5
Test for overall effect:	Z = 6.60 (F	° < 0.00	0001)				Favours (Monotherapy) Favours (AT+MT)
GURE 9							
GURE 9 Jubgroup analysis of dis	anco stago		SD) on F	MALO	utcomoc		

stands out methodologically as it incorporates nine randomized controlled studies (19, 21–23, 25, 35, 46, 47, 53) that were published after January 2023, representing 21.4% of the more recent trials. Moreover, these newer trials account for 19.7% of the total participants (676/3,440). This study further explored the relationship between treatment duration, types of AT,

and disease staging with treatment outcomes through subgroup analysis.

Our study found that longer treatment durations significantly improved FMA-L outcomes in patients (interaction P = 0.02; Figure 5). This improvement may be due to the need for sustained training to achieve neural adaptations and muscle

		T+MT			otherap			Mean Difference	Mean Difference
itudy or Subgroup	Mean	SD		Mean			-	IV, Random, 95% Cl	IV, Random, 95% Cl
an Duan 2020		14.75		47.68		47	3.6%	6.20 [0.14, 12.26]	
)aojin Xia 2021	24.5	3.03	24	17.1	3.78	24	4.7%	7.40 [5.46, 9.34]	-
lan Liu 2019	77.62	5.71		65.03	5.94	38	4.6%	12.59 [9.97, 15.21]	
ingjun Xie 2018	76.76	5.48		64.58	5.83	45	4.6%	12.18 [9.84, 14.52]	
injing Zhang 2024	60.33	4.68		44.39	4.51	60	4.7%	15.94 [13.91, 17.97]	
ei Pang 2022	70.93	11	40	62.95	10.54	80	4.2%	7.98 [3.86, 12.10]	
ixia Chen 2021	86.52	7.54	42	70.63	8.49	42	4.4%	15.89 [12.46, 19.32]	
uyao Jiang 2024.	50.58	13.23	40	44.13	13.45	40	3.7%	6.45 [0.60, 12.30]	
leng Wang 2023	74.68	14.85	31	64.42	18.4	31	3.0%	10.26 [1.94, 18.58]	
ling Zhang 2021		17.91		56.32		32	3.0%	1.78 [-6.34, 9.90]	<u> </u>
ingping Gou 2023	66.71	13.08		48.66	10.31	38	3.9%	18.05 [12.75, 23.35]	
)in Yang 2020	60.02	6.54	30	39.39	5.43	30	4.5%	20.63 [17.59, 23.67]	
uili Wen 2024	89.73	9.42	36	80.31	8.56	36	4.2%	9.42 [5.26, 13.58]	
haoyang Cui 2015	55.81	9.31	32	50.67	4.49	32	4.3%	5.14 [1.56, 8.72]	
haoyang Cui 2017	46.48	8.51	33	40.37	4.69	32	4.4%	6.11 [2.78, 9.44]	
Sheng Ge 2021	70.58	7.79	50	60.54	6.28	25	4.4%	10.04 [6.77, 13.31]	
u Zheng 2018	47.5	1.7	30	41.85	1.85	60	4.8%	5.65 [4.88, 6.42]	-
iangping Zhao 2022	69.58	10.83	45	70.07	11.94	44	4.0%	-0.49 [-5.23, 4.25]	
inting Wang 2021	53.77	8.54	30	43.55	7.69	60	4.3%	10.22 [6.60, 13.84]	
iuhua Zhang 2018	45.91	5.39	60	40.73	5.01	60	4.7%	5.18 [3.32, 7.04]	-
anan Zhang 2020	76.81	5.47	43	64.53	5.8	43	4.6%	12.28 [9.90, 14.66]	
henglu Yin 2020	68.22	8.65	51	60.94	8.77	25	4.2%	7.28 [3.10, 11.46]	
henyu Ma 2019	66.35	5.42	15	36.57	7.27	15	4.1%	29.78 [25.19, 34.37]	
hi Tan 2020	75.88	22.52	34	50.49	14.88	66	3.0%	25.39 [17.01, 33.77]	
otal (95% CI)			898			1005	100.0%	10.82 [8.52, 13.12]	◆
leterogeneity: Tau ² = 2	8.36; Chi	² = 361.	52, df=	= 23 (P <	< 0.0000	01); I ² =	94%	-	-20 -10 0 10 20
est for overall effect: Z	= 9.22 (P	< 0.00	001)						Favours (Monotherapy) Favours (AT+MT)
JRE 10		10		-					
group analysis of dis	ease sta	age (OF	vs. SF) on Fl	MA-UE	outco	mes.		

endurance in the lower limbs. Additionally, lower limb activities, such as walking and standing, involve more basic motor patterns and are relatively simpler in terms of motor control, making them more responsive to extended therapy. The longer therapy duration also provides time to gradually rebuild gait patterns and posture, which are important for functional recovery.

The results for FMA-UE, MBI, and MAS upper limb sections did not show significant correlations between treatment duration and treatment effects (interaction PFMA-UE = 0.63, PMBI = 0.70, PMAS upper limb = 0.25; Figures 6, 14, 15). This suggests that extending therapy may not be enough to improve upper limb motor function and MBI recovery. The modest effects on upper limb outcomes may be due to the complexity of upper limb rehabilitation, which involves finer motor control and neural signal modulation for the hands and arms (59–61). Furthermore, MBI reflects overall daily living abilities, which can be influenced by factors beyond motor function, such as cognitive status and environmental support. These factors may limit the extent to which extended therapy alone can lead to substantial improvements in MBI scores.

Our study found that there was no significant correlation between AT types and treatment effects for FMA-UE, FMA-L, and MBI (interaction $P_{FMA-UE} = 0.22$, $P_{FMA-L} = 0.1$, $P_{MBI} = 0.70$; Figures 7, 8, 16). SA emphasizes stimulation of specific scalp points, possibly involving indirect effects on brain functional areas through the nervous system (43, 62). In contrast, BA directly targets body points, potentially relying more on direct neural and physiological effects, such as muscle contraction regulation (63). Although theoretically these methods differ, our study did not demonstrate significant treatment efficacy differences among them. Despite the lack of observable differences in outcomes, this indirectly suggests that SA and BA may be equivalent in specific cases. Future studies should expand sample sizes and design more targeted trials to further explore differences in AT types for treating post-stroke limb functional impairments.

Our study results indicate that combined therapy for stroke patients did not significantly affect limb function recovery across different stages. Specifically, we did not observe significant differences in promoting lower limb function recovery between early intervention during the subacute phase and intervention during other phases. This finding contradicts previous research, which commonly indicates that early subacute phase intervention leads to improved recovery outcomes because of its benefits in brain plasticity and treatment time windows (60). Nevertheless, our findings indicate that while early intervention may have theoretical benefits, the actual rehabilitation procedures may be influenced by additional factors that impact the outcomes of recovery. The factors include personal variances, different approaches of treatment, and the degree of help provided during the rehabilitation process. The interaction of these elements could lead to the limited or negligible influence of the intervention timing on the recorded recovery results in our research. Moreover, our study emphasizes the need of paying more attention to the individualized rehabilitation demands and making judgments for stroke patients at several phases of clinical activity.

Many studies have shown that MT or AT alone can produce beneficial effects. For example, Madhoun et al. (64) reported that

		T+MT			otherap			Mean Difference	Mean Difference
tudy or Subgroup	Mean		Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
2.1 Course of treatm		-							
an Duan 2020	53.88			47.68		47	3.6%	6.20 [0.14, 12.26]	
aojin Xia 2021	24.5	3.03	24	17.1	3.78	24	4.7%	7.40 [5.46, 9.34]	
an Liu 2019	77.62	5.71		65.03	5.94	38	4.6%	12.59 [9.97, 15.21]	
ngjun Xie 2018	76.76	5.48		64.58	5.83	45	4.6%	12.18 [9.84, 14.52]	
njing Zhang 2024	60.33	4.68	30	44.39	4.51	60	4.7%	15.94 [13.91, 17.97]	
uyao Jiang 2024	50.58	13.23	40	44.13	13.45	40	3.7%	6.45 [0.60, 12.30]	
eng Wang 2023	74.68	14.85	31	64.42	18.4	31	3.0%	10.26 [1.94, 18.58]	
ingping Gou 2023	66.71	13.08	38	48.66	10.31	38	3.9%	18.05 [12.75, 23.35]	
in Yang 2020	60.02	6.54	30	39.39	5.43	30	4.5%	20.63 [17.59, 23.67]	
haoyang Cui 2015	55.81	9.31	32	50.67	4.49	32	4.3%	5.14 [1.56, 8.72]	
haoyang Cui 2017	46.48	8.51	33	40.37	4.69	32	4.4%	6.11 [2.78, 9.44]	
heng Ge 2021	70.58	7.79	50	60.54	6.28	25	4.4%	10.04 [6.77, 13.31]	
iangping Zhao 2022	69.58	10.83	45	70.07	11.94	44	4.0%	-0.49 [-5.23, 4.25]	
inting Wang 2021	53.77	8.54	30	43.55	7.69	60	4.3%	10.22 [6.60, 13.84]	
iuhua Zhang 2018	45.91	5.39	60	40.73	5.01	60	4.7%	5.18 [3.32, 7.04]	
anan Zhang 2020	76.81	5.47	43	64.53	5.8	43	4.6%	12.28 [9.90, 14.66]	
henyu Ma 2019	66.35	5.42	15	36.57	7.27	15	4.1%	29.78 [25.19, 34.37]	
ubtotal (95% CI)			633			664	72.2%	11.09 [8.24, 13.95]	•
eterogeneity: Tau ² = 3	1.91; Chi	² = 232.	86, df=	:16 (P <	< 0.0000	1); l² =	93%		
est for overall effect: Z	= 7.62 (P	< 0.000	001)						
2.2 Course of treatm	ent (≥6w	(eeks)							
ei Pang 2022	70.93	11	40	62.95	10.54	80	4.2%	7.98 [3.86, 12.10]	
-	86.52	7.54	42	70.63	8.49	42	4.4%	15.89 [12.46, 19.32]	
ixia Chen 2021	80.52			68.00	15.11	32	3.0%	1.78 [-6.34, 9.90]	
		17.91	32	50.3Z					
ing Zhang 2021	58.1	17.91 9.42						• • •	
ing Zhang 2021 uili Wen 2024		17.91 9.42 1.7	36	56.32 80.31 41.85	8.56	36 60	4.2% 4.8%	9.42 [5.26, 13.58]	
ing Zhang 2021 uili Wen 2024 u Zheng 2018	58.1 89.73 47.5	9.42 1.7	36	80.31 41.85	8.56 1.85	36	4.2% 4.8%	9.42 [5.26, 13.58] 5.65 [4.88, 6.42]	· · · · · · · · · · · · · · · · · · ·
ing Zhang 2021 uili Wen 2024	58.1 89.73 47.5 68.22	9.42 1.7 8.65	36 30 51	80.31 41.85	8.56 1.85 8.77	36 60	4.2% 4.8% 4.2%	9.42 [5.26, 13.58] 5.65 [4.88, 6.42] 7.28 [3.10, 11.46]	· · · · · · · · · · · · · · · · · · ·
ing Zhang 2021 uili Wen 2024 u Zheng 2018 henglu Yin 2020	58.1 89.73 47.5 68.22	9.42 1.7	36 30 51	80.31 41.85 60.94	8.56 1.85 8.77	36 60 25	4.2% 4.8% 4.2%	9.42 [5.26, 13.58] 5.65 [4.88, 6.42]	· · · · · · · · · · · · · · · · · · ·
ing Zhang 2021 uili Wen 2024 u Zheng 2018 nenglu Yin 2020 ni Tan 2020 ubtotal (95% Cl)	58.1 89.73 47.5 68.22 75.88	9.42 1.7 8.65 22.52	36 30 51 34 265	80.31 41.85 60.94 50.49	8.56 1.85 8.77 14.88	36 60 25 66 341	4.2% 4.8% 4.2% 3.0% 27.8 %	9.42 [5.26, 13.58] 5.65 [4.88, 6.42] 7.28 [3.10, 11.46] 25.39 [17.01, 33.77]	·
ing Zhang 2021 uili Wen 2024 u Zheng 2018 henglu Yin 2020 hi Tan 2020	58.1 89.73 47.5 68.22 75.88 25.12; Chi	9.42 1.7 8.65 22.52 ² = 56.7	36 30 51 34 265 4, df =	80.31 41.85 60.94 50.49	8.56 1.85 8.77 14.88	36 60 25 66 341	4.2% 4.8% 4.2% 3.0% 27.8 %	9.42 [5.26, 13.58] 5.65 [4.88, 6.42] 7.28 [3.10, 11.46] 25.39 [17.01, 33.77]	· ◆
ing Zhang 2021 uili Wen 2024 u Zheng 2018 henglu Yin 2020 hi Tan 2020 ubtotal (95% CI) eterogeneity: Tau ² = 2	58.1 89.73 47.5 68.22 75.88 25.12; Chi	9.42 1.7 8.65 22.52 ² = 56.7	36 30 51 34 265 4, df =	80.31 41.85 60.94 50.49	8.56 1.85 8.77 14.88	36 60 25 66 341 ; I ² = 89	4.2% 4.8% 4.2% 3.0% 27.8 %	9.42 [5.26, 13.58] 5.65 [4.88, 6.42] 7.28 [3.10, 11.46] 25.39 [17.01, 33.77]	• •
ing Zhang 2021 uili Wen 2024 u Zheng 2018 henglu Yin 2020 hi Tan 2020 ubtotal (95% CI) eterogeneity: Tau ² = 2 est for overall effect: Z	58.1 89.73 47.5 68.22 75.88 25.12; Chi = 4.76 (P	9.42 1.7 8.65 22.52 ² = 56.7 < 0.000	36 30 51 34 265 4, df = 001) 898	80.31 41.85 60.94 50.49 6 (P < 0	8.56 1.85 8.77 14.88 .00001)	36 60 25 66 341 ; ² = 89 1005	4.2% 4.8% 4.2% 3.0% 27.8%	9.42 (5.26, 13.58) 5.65 (4.88, 6.42) 7.28 (3.10, 11.46) 25.39 (17.01, 33.77) 10.08 (5.93, 14.23)	
ing Zhang 2021 uili Wen 2024 u Zheng 2018 henglu Yin 2020 hi Tan 2020 ubtotal (95% CI) eterogeneity: Tau ² = 2 est for overall effect: Z otal (95% CI)	58.1 89.73 47.5 68.22 75.88 25.12; Chi = 4.76 (P	9.42 1.7 8.65 22.52 ² = 56.7 < 0.000 ² = 361.	36 30 51 34 265 4, df = 001) 898 52, df =	80.31 41.85 60.94 50.49 6 (P < 0	8.56 1.85 8.77 14.88 .00001)	36 60 25 66 341 ; ² = 89 1005	4.2% 4.8% 4.2% 3.0% 27.8%	9.42 (5.26, 13.58) 5.65 (4.88, 6.42) 7.28 (3.10, 11.46) 25.39 (17.01, 33.77) 10.08 (5.93, 14.23)	-20 -10 0 10 20
ing Zhang 2021 uili Wen 2024 u Zheng 2018 henglu Yin 2020 hi Tan 2020 ubtotal (95% CI) leterogeneity: Tau ² = 2 est for overall effect: Z otal (95% CI) leterogeneity: Tau ² = 2	58.1 89.73 47.5 68.22 75.88 25.12; Chi = 4.76 (P 28.36; Chi = 9.22 (P	9.42 1.7 8.65 22.52 ² = 56.7 ² < 0.000 ² = 361. ² < 0.000	36 30 51 34 265 4, df = 001) 898 52, df = 001)	80.31 41.85 60.94 50.49 6 (P < 0 : 23 (P <	8.56 1.85 8.77 14.88 .00001)	36 60 25 66 341 ; ² = 89 1005 1); ² =	4.2% 4.8% 4.2% 3.0% 27.8%	9.42 (5.26, 13.58) 5.65 (4.88, 6.42) 7.28 (3.10, 11.46) 25.39 (17.01, 33.77) 10.08 (5.93, 14.23)	-20 -10 0 10 20 Favours [Monotherapy] Favours [AT+MT]
ing Zhang 2021 uili Wen 2024 u Zheng 2018 henglu Yin 2020 hi Tan 2020 ubtotal (95% CI) leterogeneity: Tau ² = 2 est for overall effect: Z otal (95% CI) eterogeneity: Tau ² = 2 est for overall effect: Z	58.1 89.73 47.5 68.22 75.88 25.12; Chi = 4.76 (P 28.36; Chi = 9.22 (P	9.42 1.7 8.65 22.52 ² = 56.7 ² < 0.000 ² = 361. ² < 0.000	36 30 51 34 265 4, df = 001) 898 52, df = 001)	80.31 41.85 60.94 50.49 6 (P < 0 : 23 (P <	8.56 1.85 8.77 14.88 .00001)	36 60 25 66 341 ; ² = 89 1005 1); ² =	4.2% 4.8% 4.2% 3.0% 27.8%	9.42 (5.26, 13.58) 5.65 (4.88, 6.42) 7.28 (3.10, 11.46) 25.39 (17.01, 33.77) 10.08 (5.93, 14.23)	
ing Zhang 2021 uili Wen 2024 u Zheng 2018 henglu Yin 2020 hi Tan 2020 ubtotal (95% CI) leterogeneity: Tau ² = 2 est for overall effect: Z otal (95% CI) eterogeneity: Tau ² = 2 est for overall effect: Z	58.1 89.73 47.5 68.22 75.88 25.12; Chi = 4.76 (P 28.36; Chi = 9.22 (P	9.42 1.7 8.65 22.52 ² = 56.7 ² < 0.000 ² = 361. ² < 0.000	36 30 51 34 265 4, df = 001) 898 52, df = 001)	80.31 41.85 60.94 50.49 6 (P < 0 : 23 (P <	8.56 1.85 8.77 14.88 .00001)	36 60 25 66 341 ; ² = 89 1005 1); ² =	4.2% 4.8% 4.2% 3.0% 27.8%	9.42 (5.26, 13.58) 5.65 (4.88, 6.42) 7.28 (3.10, 11.46) 25.39 (17.01, 33.77) 10.08 (5.93, 14.23)	

MT aids in upper limb motor recovery after stroke. Similarly, Yang et al. (65) found that acupuncture activates relevant neurons and enhances motor function. However, combining AT and MT has been shown to be more effective than either therapy alone for post-stroke movement disorders (25). Our systematic evaluation further confirmed the strong therapeutic potential of this combined approach, particularly in improving motor function. This provides a solid foundation for future studies with larger and more diverse populations.

Strengths and limitations

The main limitation of this study is that the assessments were derived from subjective scales. In addition, the use of subjective scales in the assessment process may have contributed to some variability in results, as assessors might not have followed the uniform procedure strictly, even though standardized guidelines exist for scales like the FMA. The assessors were independent individuals with unique expertise and experience from a variety of trials.Secondly, subjective measures include various assessment factors but lack specificity and detail in capturing treatment effects (66). This limits their ability to provide a comprehensive evaluation. Furthermore, a single subjective scale cannot fully reflect individual differences and changes in patient conditions. Thus, it is necessary to integrate objective indicators, such as EMG systems, gait analysis, and fMRI, to gain a more comprehensive view. However, due to the high cost and limited accessibility of these devices, subjective scales remain the primary assessment method (67–70).

The other limitations of this study are as follows. Due to the different clinical presentations of stroke patients, the AT points or methods used during treatment vary greatly among individuals, making it difficult to avoid variations in treatment efficacy even within the same trial. Clinically, the subacute phase of stroke is considered one of the optimal times for treatment (60), leading researchers to focus more on the rehabilitation of patients in the subacute phase during trials. As a result, only a limited number of studies included patients in the acute and chronic phases in this research.

The strength of this study lies in its ability to capitalize on the value of the available data. The subgroup analyses consisted of three components: duration of treatment, type of AT, and stage of disease. The data obtained from these subgroup analyses provide clinicians with reliable recommendations for making treatment decisions.

	1	\T+MT		Mor	otherap	у		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
3.4.1 SP									
Can Duan 2020	35.06	11.88	49	30.11	11.63	47	3.0%	4.95 [0.25, 9.65]	
Daojin Xia 2021	41.5	6.8	24	31.6	6.04	24	3.7%	9.90 [6.26, 13.54]	
Han Liu 2019	46.17	3.86	38	38.49	2.15	38	5.4%	7.68 [6.28, 9.08]	
Hangfan Zhou 2017	34.97	7.85	20	23.88	8.78	40	3.2%	11.09 [6.70, 15.48]	
Jianming Li 2022	28.32	5.64	47	17.62	5.14	47	4.8%	10.70 [8.52, 12.88]	
Jingjun Xie 2018	45.96	4.03	45	38.58	1.98	45	5.4%	7.38 [6.07, 8.69]	
Jinjing Zhang 2024	26.23	1.77	30	21.92	2.74	60	5.6%	4.31 [3.37, 5.25]	-
Meng Wang 2023	29.58	13.79	31	21.52	12.81	31	2.0%	8.06 [1.43, 14.69]	
Pingping Gou 2023	42.23	8.76	38	31.84	6.09	38	3.9%	10.39 [7.00, 13.78]	
Qiong Luo 2020	28.05	3.81	48	25.72	3.54	48	5.3%	2.33 [0.86, 3.80]	
Rui Zhang 2017	47.7	9.71	20	29.8	9.68	40	2.7%	17.90 [12.69, 23.11]	
Shaoyang Cui 2015	31.66	4.64	32	26.75	4.73	32	4.8%	4.91 [2.61, 7.21]	
Weidong Yang 2019	42.32	7.67	30	36.34	0.95	30	4.4%	5.98 [3.21, 8.75]	
Xiaoli Song 2024	39.6	8.72	40	32.63	7.25	40	3.8%	6.97 [3.46, 10.48]	
Xinting Wang 2021	35.93	3.5	30	31.1	5.03	60	5.1%	4.83 [3.04, 6.62]	
Xiping Zhang 2018	50.9	8	31	42	7.9	31	3.5%	8.90 [4.94, 12.86]	
Zhenglu Yin 2020	40.75	7.18	51	32.54	7.36	25	3.8%	8.21 [4.72, 11.70]	
Zhenyu Ma 2019	31.13	6.54	20	28.23	3.23	20	4.1%	2.90 [-0.30, 6.10]	
Subtotal (95% CI)			624			696	74.6%	7.23 [5.82, 8.64]	◆
Heterogeneity: Tau ² =	6.75; Ch	i² = 110	.59, df:	= 17 (P	< 0.000	01); I ² =	85%		
Test for overall effect:)	Z = 10.08	8 (P < 0.	00001)						
3.4.2 OP									
Ning Xu 2021	40.73	4.91	38	34.82	4.44	38	4.9%	5.91 [3.81, 8.01]	
Ning Zhang 2021	44.21	2.6	32	40.85	3.2	32	5.4%	3.36 [1.93, 4.79]	
Qiang He 2023	55.6	6.45	55	44.86	4.4	55	4.9%	10.74 [8.68, 12.80]	
Su Zheng 2018	37.5	1.8	30	33.5	1.59	60	5.7%	4.00 [3.24, 4.76]	+
Yanan Zhang 2021	34.51	6.62	43	30.81	5.93	43	4.5%	3.70 [1.04, 6.36]	
Subtotal (95% CI)			198			228	25.4%	5.49 [3.20, 7.78]	•
Heterogeneity: Tau² =				4 (P < 0).00001)); I² = 9I	0%		
Test for overall effect: .	2 = 4.69	(P < 0.0	0001)						
Total (95% CI)			822			924	100.0 %	6.77 [5.60, 7.93]	•
Heterogeneity: Tau² =					< 0.000	01); I² =	87%		-20 -10 0 10 20
Test for overall effect:)									Favours (Monotherapy) Favours (AT+MT)
Test for subgroup diffe	erences:	Chi ² = 1	.61, df	= 1 (P =	: 0.20), I	² = 37.8	3%		, areas (nononisiabil) i aroas (ni ini)
URE 12									

	A	T+MT			othera			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
2.4.1 SP									
Aijun Wang 2022	25.33	5.07	54	22.57	6.62	54	3.0%	2.76 [0.54, 4.98]	
Di Zhu 2019	26.6	3.7	40	22.45	4.09	80	6.9%	4.15 [2.69, 5.61]	
Lixia Chen 2021	27.63	2.52	42	22.63	4.82	42	5.4%	5.00 [3.36, 6.64]	
Lixia Chen 2022	29.26	4.23	50	25.78	3.81	50	5.9%	3.48 [1.90, 5.06]	
(iaoli Song 2024	25.48	5.04	40	21.75	4.53	40	3.3%	3.73 [1.63, 5.83]	
(iping Zhang 2018	22.39	3.27	60	19.65	3.61	60	9.6%	2.74 [1.51, 3.97]	
Subtotal (95% Cl)			286			326	34.0%	3.61 [2.95, 4.26]	•
Heterogeneity: Chi ² =	5.79, df :	= 5 (P :	= 0.33)	; l² = 149	%				
Fest for overall effect:	Z = 10.8	0 (P <	0.0000	1)					
2.4.2 OP									
Keyong Cao 2022	25.04	4.69	27	19.74	3.73	54	3.5%	5.30 [3.27, 7.33]	
/lingzhu Xu 2023	24.3	1.3	28	21.05	0.97	58	49.6%	3.25 [2.71, 3.79]	
Qin Yang 2020	27.39	2.43	30	25.25	2.32	30	10.1%	2.14 [0.94, 3.34]	— —
Shaoyang Cui 2017	22.37	4.83		17.64	4.65	32	2.7%	4.73 [2.43, 7.03]	
Subtotal (95% CI)			118			174	66.0 %	3.25 [2.78, 3.72]	•
Heterogeneity: Chi² =				•	%				
Fest for overall effect:	Z = 13.5	5 (P <	0.0000	1)					
otal (95% Cl)			404			500	100.0 %	3.37 [2.99, 3.76]	•
Heterogeneity: Chi ² =	15.32, di	f = 9 (F	P = 0.08	3); I ² = 41	1%				
Test for overall effect:	Z=17.3	1 (P <	0.0000	1)					-4 -2 0 2 4 Favours (Monotherapy) Favours (AT+MT)
Test for subgroup diff	erences:	Chi²=	0.76,	df = 1 (P	= 0.38	3), l² = (0%		
URE 13									
rest plot of total effe	ctivo rat	0.000	noring		T with	contr	ol intoruc	un til nun n	

	A	T+MT		Mone	othera	ру		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
2.3.1 SA									
Aijun Wang 2022	25.33	5.07	54	22.57	6.62	54	3.0%	2.76 [0.54, 4.98]	
Di Zhu 2019	26.6	3.7	40	22.45	4.09	80	6.9%	4.15 [2.69, 5.61]	
Lixia Chen 2021	27.63	2.52	42	22.63	4.82	42	5.4%	5.00 [3.36, 6.64]	
Lixia Chen 2022	29.26	4.23	50	25.78	3.81	50	5.9%	3.48 [1.90, 5.06]	
Subtotal (95% CI)			186			226	21.1%	3.99 [3.16, 4.82]	•
Heterogeneity: Chi² =	3.07, df =	= 3 (P =	= 0.38)	l² = 2%	,				
Test for overall effect:	Z = 9.39	(P < 0.	.00001)					
2.3.2 BA									
Keyong Cao 2022	25.04	4.69	27	19.74	3.73	54	3.5%	5.30 [3.27, 7.33]	
Mingzhu Xu 2023	24.3	1.3	28	21.05	0.97	58	49.6%	3.25 [2.71, 3.79]	
Qin Yang 2020	27.39	2.43	30	25.25	2.32	30	10.1%	2.14 [0.94, 3.34]	
Shaoyang Cui 2017	22.37	4.83	33	17.64	4.65	32	2.7%	4.73 [2.43, 7.03]	
Xiaoli Song 2024	25.48	5.04	40	21.75	4.53	40	3.3%	3.73 [1.63, 5.83]	
Xiuhua Zhang 2018	22.39	3.27		19.65	3.61	60	9.6%	2.74 [1.51, 3.97]	
Subtotal (95% CI)			218			274	78.9%	3.21 [2.78, 3.64]	•
Heterogeneity: Chi² =	9.60, df =	= 5 (P =	= 0.09)	² = 48'	%				
Test for overall effect:	Z=14.6	3 (P < I	0.0000	1)					
Total (95% CI)			404			500	100.0%	3.37 [2.99, 3.76]	•
Heterogeneity: Chi ² =	15.32, di	f = 9 (P	= 0.08	(); $l^2 = 4^{\circ}$	1%			-	-4 -2 0 2 4
Test for overall effect:	Z=17.3	1 (P < I	0.0000	1)					-4 -2 U 2 4 Favours (Monotherapy) Favours (AT+MT)
Test for subgroup diff	erences:	Chi ² =	2.65,	df = 1 (P	= 0.10	0), I ² = 8	32.2%		ravous (monourerapy) ravous (Ar+MT)
URE 14									
bgroup analysis of tr	eatment	durati	ion on	MRLO	tcom	20			



Implications

The FMA series scale scores are the most significant outcome of this analysis, demonstrating that in our study, stroke patients experienced significant improvements in both upper and lower limb functions following combined AT and MT treatment. Furthermore, in our course-of-treatment subgroup analysis, we found that the efficacy of treatment for lower limb dysfunction is related to the duration of therapy, suggesting that the effects of the combined treatment plan can accumulate for the lower limbs.Conversely, the effectiveness of treatment for upper limb dysfunction was not significantly correlated with treatment duration, suggesting that if the course of treatment extends beyond a certain threshold (e.g., 6–8 weeks), other more effective strategies could be implemented. This approach can optimize resource allocation and reduce patient costs. Additionally, our

	1	T+MT			othera	-		Mean Difference	Mean Difference
itudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
I.3.1 SA									
Can Duan 2020	53.88	14.75	49	47.68	15.53	47	3.6%	6.20 [0.14, 12.26]	
lingjun Xie 2018	76.76	5.48	45	64.58	5.83	45	4.6%	12.18 [9.84, 14.52]	
ei Pang 2022.	70.93	11	40	62.95	10.54	80	4.2%	7.98 [3.86, 12.10]	_ →
ixia Chen 2021	86.52	7.54	42	70.63	8.49	42	4.4%	15.89 [12.46, 19.32]	
Sheng Ge 2021	70.58	7.79	50	60.54	6.28	25	4.4%	10.04 [6.77, 13.31]	
(inting Wang 2021	53.77	8.54	30	43.55	7.69	60	4.3%	10.22 [6.60, 13.84]	
Zhenglu Yin 2020	68.22	8.65	51	60.94	8.77	25	4.2%	7.28 [3.10, 11.46]	
Thi Tan 2020	75.88	22.52	34	50.49	14.88	66		25.39 [17.01, 33.77]	
Subtotal (95% CI)			341			390	32.8%	11.28 [8.51, 14.05]	
Heterogeneity: Tau ^z = 1 Test for overall effect: Z				7 (P = 0	.0002);	I² = 759	6		
I.3.2 BA									
Daojin Xia 2021	24.5	3.03	24	17.1	3.78	24	4.7%	7.40 [5.46, 9.34]	-
Han Liu 2019	77.62	5.71	38	65.03	5.94	38	4.6%	12.59 [9.97, 15.21]	
linjing Zhang 2024	60.33	4.68	30	44.39	4.51	60	4.7%	15.94 [13.91, 17.97]	
uyao Jiang 2024.	50.58	13.23	40	44.13	13.45	40	3.7%	6.45 (0.60, 12.30)	
leng Wang 2023	74.68	14.85		64.42	18.4	31	3.0%	10.26 [1.94, 18.58]	
Ving Zhang 2021	58.1	17.91	32	56.32	15.11	32	3.0%	1.78 [-6.34, 9.90]	
Pingping Gou 2023	66.71	13.08		48.66	10.31	38	3.9%	18.05 [12.75, 23.35]	
Qin Yang 2020	60.02	6.54	30	39.39	5.43	30	4.5%	20.63 [17.59, 23.67]	
Ruili Wen 2024	89.73	9.42		80.31	8.56	36	4.2%	9.42 [5.26, 13.58]	
Shaoyang Cui 2015	55.81	9.31	32	50.67	4.49	32	4.3%	5.14 [1.56, 8.72]	
Shaoyang Cui 2017	46.48	8.51	33	40.37	4.69	32	4.4%	6.11 [2.78, 9.44]	
Su Zheng 2018	47.5	1.7	30	41.85	1.85	60	4.8%	5.65 [4.88, 6.42]	+
(iangping Zhao 2022	69.58	10.83	45	70.07	11.94	44	4.0%	-0.49 [-5.23, 4.25]	
(iuhua Zhang 2018	45.91	5.39	60	40.73	5.01	60	4.7%	5.18 [3.32, 7.04]	-
ʻanan Zhang 2020	76.81	5.47	43	64.53	5.8	43	4.6%	12.28 [9.90 , 14 .66]	
Thenyu Ma 2019	66.35	5.42		36.57	7.27	15	4.1%		
Subtotal (95% Cl)			557			615	67.2%	10.49 [7.50, 13.48]	•
Heterogeneity: Tau ² = 3 Fest for overall effect: Z				= 15 (P <	× 0.000(01); I ^z =	95%		
otal (95% CI)			898			1005	100.0%	10.82 [8.52, 13.12]	•
Heterogeneity: Tau ² = 2	3.36; Chi	² = 361.	52, df=	= 23 (P <	< 0.0000	01); I ≃ =	94%		
est for overall effect: Z	•			`					-20 -10 Ó 10 20 Favouro Monotherand, Favouro MT, MT
Test for subgroup differ				1 (P = 0).70), I ≧:	= 0%			Favours [Monotherapy] Favours [AT+MT]
eacheap allo									
URE 16									
ogroup analysis of AT									

subgroup analysis of AT types showed no significant difference in patient outcomes between using SA or BA. Clinically, as different patients have varying tolerances to AT, physicians can now choose different treatment plans for limb dysfunction based on the patient's tolerance to AT.In the disease staging subgroup analysis, there was no significant difference in upper or lower limb dysfunction, indicating that this treatment regimen is appropriate for stroke patients at any clinical stage.

In terms of clinical efficacy, our study shows that after combined AT and MT treatment, the clinical efficacy rate of stroke patients was higher compared to the control group. In the disease staging subgroup analysis, there was no significant difference in clinical efficacy rates among stroke patients at different stages, suggesting that this approach is suitable for efficacy in all stages of stroke, making this protocol a viable treatment throughout the entire clinical phase of stroke patients.

MBI is a vital observational measure that is associated with patients' ability to do their everyday activities. The results of our study indicate that stroke patients experienced notable enhancements in their ability to do daily tasks after receiving a combination of AT and MT. Subgroup analysis, considering the period of treatment, revealed no notable disparities in the degree of improvement across patients. This implies that after an adequate duration of treatment (e.g., 6-8 weeks), exploring more potent alternative methods may help further enhance patients' daily functioning. Doing so can prevent unnecessary medical resource allocation and reduce treatment costs for patients. There were also no significant differences between SA and BA versions of AT, indicating that healthcare providers can select the treatment approach based on the patient's individual tolerance and preference, without compromising therapeutic outcomes. In addition, when subgroup analysis was conducted based on illness stage, there were no notable disparities in the enhancement of daily living skills among stroke patients at all stages. This indicates that the treatment plan is appropriate for all stages of stroke. Thus, this therapy regimen offers a viable choice that can be utilized throughout all stages of stroke patients' clinical progression.

MAS is a crucial observational indicator related to the degree of spasticity in patients' limbs. Our study indicates that following combined AT and MT therapy, stroke patients showed significant improvements in the degree of limb spasticity. Subgroup analysis based on AT type revealed no significant differences in the degree of limb spasticity among patients, suggesting that clinical

	1	AT+MT		Mon	Monotherapy			Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	
4.4.1 SP										
Can Duan 2020	53.88	14.75	49	47.68	15.53	47	3.6%	6.20 [0.14, 12.26]		
Daojin Xia 2021	24.5	3.03	24	17.1	3.78	24	4.7%	7.40 [5.46, 9.34]	-	
Han Liu 2019	77.62	5.71	38	65.03	5.94	38	4.6%	12.59 [9.97, 15.21]		
Jingjun Xie 2018	76.76	5.48	45	64.58	5.83	45	4.6%	12.18 [9.84, 14.52]		
Jinjing Zhang 2024	60.33	4.68	30	44.39	4.51	60	4.7%	15.94 [13.91, 17.97]		
Lei Pang 2022	70.93	11.56	40	62.95	10.54	80	4.2%	7.98 [3.72, 12.24]	→	
Lixia Chen 2021	86.52	7.54	42	70.63	8.49	42	4.4%	15.89 [12.46, 19.32]		
Luyao Jiang 2024	50.58	13.23	40	44.13	13.45	40	3.7%	6.45 [0.60, 12.30]		
Meng Wang 2023	74.68	14.85	31	64.42	18.4	31	3.0%	10.26 [1.94, 18.58]		
Pingping Gou 2023	66.71	13.08	38	48.66	10.31	38	3.9%	18.05 [12.75, 23.35]		
Shaoyang Cui 2015	55.81	9.31	32	50.67	4.49	32	4.4%	5.14 [1.56, 8.72]	- - -	
Sheng Ge 2021	70.58	7.79	50	60.54	6.28	25	4.4%	10.04 [6.77, 13.31]		
Xiangping Zhao 2022	69.58	10.83	45	70.07	11.94	44	4.0%	-0.49 [-5.23, 4.25]	+	
Xinting Wang 2021	53.77	8.54	30	43.55	7.69	60	4.3%	10.22 [6.60, 13.84]		
Yanan Zhang 2020	76.81	5.47	43	64.53	5.8	43	4.6%	12.28 [9.90, 14.66]		
Zhenglu Yin 2020	68.22	8.65	51	60.94	8.77	25	4.2%	7.28 [3.10, 11.46]	_ →	
Zhenyu Ma 2019	66.35	5.42	15	36.57	7.27	15	4.1%	29.78 [25.19, 34.37]		
Subtotal (95% CI)			643			689	71.4%	11.09 [8.51, 13.67]	•	
Heterogeneity: Tau ² = 25 Test for overall effect: Z = 4.4.2 OP				- 10 (F	~ 0.0000	, , , , , , , , , , , , , , , , , , ,	50%			
Ning Zhang 2021	58.1	17.91	32	56.32	15.11	32	3.0%	1.78 [-6.34, 9.90]		
Qin Yang 2020	60.02			39.39	5.43	30		20.63 [17.59, 23.67]		
Ruili Wen 2024	89.73	9.42	36	80.31	8.56	36	4.2%	9.42 [5.26, 13.58]		
Shaoyang Cui 2017	46.48	8.51	33	40.37	4.69	32	4.4%	6.11 [2.78, 9.44]		
Su Zheng 2018	47.5	1.7	30	41.85	1.85	60	4.8%	5.65 [4.88, 6.42]	-	
Xiuhua Zhang 2018	45.91	5.39	60	40.73	5.01	60	4.7%	5.18 [3.32, 7.04]		
Zhi Tan 2020	75.88	22.52	34	50.49	14.88	66	3.0%			
Subtotal (95% CI)			255			316	28.6%	10.18 [5.84, 14.52]		
Heterogeneity: Tau ² = 28				=6(P <	0.00001	l); ² = 9	35%			
Test for overall effect: Z =			898			1005	100.0%	10.82 [8.52, 13.13]	▲	
Total (95% CI)							.00.070	10:02 [0:02, 10:10]		

Subgroup analysis of disease stage (OP vs. SP) on MBI outcomes.

	AT+N	AT	Monothe	rapy		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
.2.1 SP							
lingjun Xie 2018	40	45	31	45	13.8%	1.29 [1.03, 1.61]	_
injing Zhang 2024	29	30	21	30	9.3%	1.38 [1.08, 1.76]	
ixia Chen 2022	48	50	36	50	16.0%	1.33 [1.11, 1.60]	
iong Luo 2020	46	48	39	48	17.3%	1.18 [1.02, 1.37]	
Veidong Yang 2019	29	30	23	30	10.2%	1.26 [1.02, 1.55]	
Subtotal (95% CI)		203		203	66.7%	1.28 [1.17, 1.40]	
Total events	192		150				
Heterogeneity: Chi ^z = 1	1.76, df = -	4 (P = 0).78); I ^z = C	196			
Fest for overall effect: J	Z = 5.50 (P	° < 0.00	0001)				
.2.2 OP							
Ving Xu 2021	32	38	23	38	10.2%	1.39 [1.04, 1.86]	
Ving Zhang 2021	26	32	19	32	8.4%	1.37 [0.98, 1.91]	
ʻanan Zhang 2020	41	43	33	43	14.7%	1.24 [1.04, 1.48]	
Cubtotol (0E0/ CD		113		113	33.3%	1.32 [1.14, 1.53]	
Subtotal (95% CI)							
	99		75				
Subtotal (95% CI) Fotal events Heterogeneity: Chi² = I		2 (P = 0		1%			
Total events	0.62, df = 3).73); I ² = 0	1%			
Total events Heterogeneity: Chi ^a = 1 Test for overall effect: 2	0.62, df = 3).73); I ² = 0		100.0%	1.29 [1.20, 1.40]	•
Total events Heterogeneity: Chi ² = 1 Test for overall effect: J T otal (95% CI)	0.62, df = 3	P = 0.00).73); I ² = 0		100.0%	1.29 [1.20, 1.40]	•
fotal events Heterogeneity: Chi² = I	0.62, df = : Z = 3.72 (F 291	P = 0.00 316).73); I² = 0 002) 225	316	100.0%	1.29 [1.20, 1.40]	
Total events Heterogeneity: Chi ² = 1 Test for overall effect: 2 Total (95% CI) Total events	0.62, df = : Z = 3.72 (F 291 2.48, df = 1	P = 0.00 316 7 (P = 0	0.73); I² = 0 002) 225 0.93); I² = 0	316	100.0%	1.29 [1.20, 1.40]	0.7 0.85 1 1.2 1.5 Favours (Monotherapy) Favours (AT+MT)

FIGURE 18

Subgroup analysis of disease stage (OP vs. SP) on Total effective rate outcomes.

practitioners can tailor treatment approaches for spasticity issues based on individual patient tolerance to AT.

Suggestions for future studies

In future research, it is crucial for scientists to carefully consider the complexities of trial design, with a main emphasis on optimizing the use of assessment tools to evaluate the efficacy of therapies. Implementing this method has the capacity to enhance the objectivity of outcome measurements, hence enhancing the accuracy and dependability of the trials. In addition, researchers should contemplate enlarging the sample sizes to encompass a greater number of patients other stage. Implementing this strategy would result in more accurate trial conclusions and facilitate the investigation of the treatment regimen's suitability for different stages of stroke.

Conclusions

In summary, researchers have found that combined AT and MT therapy is effective as a novel treatment approach for addressing post-stroke motor impairments. Future studies of larger scale and greater precision are necessary to yield more accurate conclusions.

Data availability statement

The data analyzed in this study is subject to the following licenses/restrictions: we can't disclose it because it involves the patient's privacy. Requests to access these datasets should be directed to Weihao Ke, 804791727@qq.com.

Author contributions

WK: Data curation, Methodology, Writing – original draft, Writing – review & editing. HC: Data curation, Writing – review & editing. XR: Data curation, Investigation, Writing – review & editing. LY: Data curation, Writing – review & editing. XL: Data curation, Writing – review & editing. ZW: Supervision, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study

References

2. Thijs L, Voets E, Denissen S, Mehrholz J, Elsner B, Lemmens R, et al. Trunk training following stroke. Stroke. (2023) 54(9):2000-5. doi: 10.1161/STROKEAHA.123.043490

received funding from the Chongqing Natural Science Foundation (CSTB2024NSCQ-MSX0504) and the National Natural Science Foundation of China (NSFC No.81674066. This study received funding from the Chongqing Natural Science Foundation (CSTB2024NSCQ-MSX0504) and the National Natural Science Foundation of China (NSFC No.81674066).

Acknowledgments

I would like to express my gratitude to OpenAI for providing the generative AI technology that assisted in the proofreading and editing of this manuscript. Specifically, I utilized ChatGPT, based on the GPT-4 architecture, version 4.0. This technology significantly improved the clarity and quality of the text. The assistance of ChatGPT was instrumental in ensuring the manuscript met the high standards required for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI Statement

The author(s) declare that Generative AI was used in the creation of this manuscript. ChatGPT 4.0 was used to proofread the manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fresc.2024. 1464502/full#supplementary-material

4. World Health Organization (WHO). The top 10 Ccauses of Ddeath. Geneva: World Health Organization (WHO) (2020). Available online at: https://www.who.

^{1.} Correction to: 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. *Circulation*. (2024) 149(19):1010–5. doi: 10.1161/CIR.000000000001247. Erratum for: *Circulation*. (2024) 149(8):450–5. doi: 10.1161/CIR.000000000001209

^{3.} Zhang Y, Zhao W, Wan C, Wu X, Huang J, Wang X, et al. Exoskeleton rehabilitation robot training for balance and lower limb function in sub-acute stroke patients: a pilot, randomized controlled trial. *J Neuroeng Rehabil.* (2024) 21 (1):98. doi: 10.1186/s12984-024-01391-0

int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed March 10, 2020).

5. Dobkin BH. Strategies for stroke rehabilitation. Lancet Neurol. (2004) 3 (9):528-36. doi: 10.1016/S1474-4422(04)00851-8

6. National Institute for Health and Care Excellence (NICE). *Stroke Rrehabilitation in Aadults*. NICE guideline NG236. London: National Institute for Health and Care Excellence (NICE) (2023). Available online at: NICE Guidelines.

7. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ American stroke association. *Stroke*. (2018) 49(3):e46–110. doi: 10.1161/STR. 000000000000158

8. World Health Organization. Acupuncture: Review and Aanalysis Rreports on Ccontrolled Cclinical Ttrials. Geneva: WHO (2002).

9. Lv Q, Xu G, Pan Y, Liu T, Liu X, Miao L, et al. Effect of acupuncture on neuroplasticity of stroke patients with motor dysfunction: a meta-analysis of fMRI studies. *Neural Plast.* (2021) 2021:8841720. doi: 10.1155/2021/8841720

10. Bonafede M, Dick A, Noyes K, Klein JD, Brown T. The effect of acupuncture utilization on healthcare utilization. *Med Care.* (2008) 46(1):41-8. doi: 10.1097/MLR.0b013e3181589b7d

11. Lee MT, Chen CC, Lu HL, Hsieh YW. Comparisons of three different modes of digital mirror therapy for post-stroke rehabilitation: preliminary results of randomized controlled trial. *Digit Health.* (2024) 10:20552076241260536. doi: 10.1177/20552076241260536

12. Judi ZK, Lixuan W, Junlin Z, Tongcai T. Efficacy observation of mirror therapy combined with scalp acupuncture in rehabilitation training for lower limb function in patients post-stroke. *Chin J Rehabil Med.* (2019) 34(5):533–8. doi: 10.3969/j.issn.1001-1242.2019.05.007

13. Peng Y, Li N, Du X, Zhang G, Huang S, Ma J. Acupuncture combined with mirror therapy for post-stroke dyskinesia: a meta-analysis and systematic review. *Medicine (Baltimore).* (2024) 103(26):e38733. doi: 10.1097/MD.000000000038733

14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Br Med J.* (2021) 372:n71. doi: 10.1136/bmj.n71

15. Shinichi A. Cochrane handbook for systematic reviews of interventions. Online Kensaku. (2014) 35:154-5.

16. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Schünemann HJ, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *Br Med J.* (2008) 336:924–6. doi: 10.1136/bmj.39489.470347.AD

17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* (2002) 21:1539–58. doi: 10.1002/sim.1186

18. Weidong Y, Yanjie M. Observation on the efficacy of electroacupuncture combined with mirror therapy in treating stage I shoulder-hand syndrome post-stroke. *Shanghai J Acupun Moxibus*. (2019) 38(5):492–6. doi: 10.13460/j.issn.1005-0957.2019.05.0492

19. Meng W, Yulin Q, Hong L, Long Y, Hao W, Tao Y. Efficacy of "regulating yin and yang" acupuncture combined with mirror therapy in treating wrist-hand dysfunction post-stroke. *Chin J Phys Med Rehabil.* (2023) 45(11):982–5. doi: 10. 3969/j.issn.1008-8296.2018.04.010

20. Ning X, Weihua D, Yun G, Weifang W. Efficacy analysis of moxibustion combined with mirror therapy-based upper limb force feedback motor control training on upper limb function recovery in patients with acute ischemic stroke. *J Hunan Univ Chin Med.* (2021) 41(9):1361–4. doi: 10.3969/j.issn.1674-070X.2021.09.009

21. Ruili W, Qibo C, Qiang L, Li C, Hong G, Wanqian L. Effects of fu zheng bu tu acupuncture combined with task-oriented mirror therapy on upper limb function in elderly patients with hemiparesis post-stroke. *Hebei J Trad Chin Med.* (2024) 46 (3):460–3. doi: 10.3969/j.issn.1002-2619.2024.03.024

22. Luyao J, Qimei L, Jiangbiao H, Lujing Y, Saixuan C, Meili Z. Effects of hegu needling method combined with mirror therapy on hand function in patients during the recovery phase of stroke. *Zhejiang Clin Med.* (2024) 26(1):42–4.

23. Huimin C, Ting M, Tian Y, Jin S, Yongqing K, Haokun L, et al. Rehabilitation efficacy of interactive scalp acupuncture combined with mirror therapy on upper limb dysfunction in patients with flaccid hemiplegia post-stroke. *Shenzhen J Integr Trad Chin Western Med.* (2023) 33(6):4–7. doi: 10.16458/j.cnki.1007-0893.2023.06.002

24. Zhenglu Y, Zhaoxiang M, Sheng G, Minjie Z, Linghui H. Clinical observation of interactive scalp acupuncture combined with task-oriented mirror therapy in treating upper limb dysfunction in ischemic stroke hemiplegia. *Chin Acupunc Moxibus*. (2020) 40(9):918–22. doi: 10.13703/j.0255-2930.20190819-0001

25. Mingzhu X, Run L, Huaneng W, Yixiao W, Lu L, Bihan W, et al. Effect of Jin San needle combined with mirror therapy on lower limb dysfunction in patients with cerebral infarction based on surface electromyography analysis. *Chin Gen Pract.* (2023) 26(17):2162–8. doi: 10.12114/j.issn.1007-9572.2023.0064

26. Xiangping Z, Xiaojun W, Xing L, Jing W, Yun L, Yanhong M, et al. Effects of left-right complementary acupuncture based on mirror neuron theory on unilateral neglect after stroke. *Massage Rehab Med.* (2022) 13(19):34–7.

27. Shaoyang C, Mingzhu X, Shenghui Z, Xinsheng L, Chunzhi T, Shuhui W, et al. Effects of jin san needle combined with mirror therapy on upper limb and hand dysfunction in hemiplegic patients. *Chin J Phys Med Rehab.* (2015) 37(7):550–1. doi: 10.3760/cma.j.issn.0254-1424.2017.08.006

28. Rui Z, Meilan Z, Ying Y, Bangliang L, Lianhua W. Effect of mirror therapy combined with tongdu Xingshen acupuncture on upper limb function recovery in patients after stroke. *Chin J Phys Med Rehab.* (2017) 39(8):588–93. doi: 10.19787/j. issn.1008-1879.2022.19.007

29. Xiping Z, Chen P, Jianping X, Fanglun S. Effect of mirror therapy combined with acupoint embedding on upper limb motor function recovery in patients with hemiplegia after stroke. *Chin Rural Med.* (2018) 25(21):16–7. doi: 10.3969/j.issn. 1674-6449.2017.04.020

30. Hangfan Z, Hanxiao Y. Efficacy of mirror therapy combined with acupuncture on upper limb function in early hemiplegic patients. *Health Res.* (2017) 37(4):427–9. doi: 10.19787/j.issn.1008-1879.2022.22.004

31. Keyong C, Wenya X, Qixun W, Peng Z. Observation on the efficacy of mirror therapy combined with acupuncture therapy on ankle dorsiflexion ability of the affected side in stroke patients. *Massage Rehab Med.* (2022) 13(22):13–6. doi: 10. 3969/j.issn.1008-8849.2024.05.016

32. Hu J, Lin YS, Xu CQ, Lyu HY, Xu SF. Effect of mirror therapy combined with neuromuscular electrical stimulation on the functional recovery of lower limbs in stroke patients with hemiplegia. *Chin J Gen Prac.* (2022) 20(7):1131–4. doi: 10. 16766/j.cnki.isn.1674-4152.002540

33. Xinfang S, Guirong X, Renyang Z. Clinical study of mirror movement therapy on motor function recovery in patients with cerebral infarction. *Chin J Neuroimmunol Neurol.* (2015) 22(2):146–7. doi: 10.3969/j.issn.1006-9771.2021.11.012

34. Su Z, Jing X, Li P. Effect of staged acupuncture combined with mirror therapy on upper limb motor function in patients with cerebral infarction and SPECT study. *Acupunct Clin J.* (2018) 34(2):24–8. doi: 10.1155/2021/9487319

35. Song XL, Yang XM, Ran DW, Ding Y. Efficacy of twelve needles of hands and feet combined with mirror therapy in the treatment of hemiplegia after stroke and its effect on hemorheology, basic fibroblast growth factor, and homocysteine. *Modern J Integ Trad Chin Western Med.* (2024) 33(5):685–9. doi: 10.1016/j.rehab.2019.10.005

36. Xia DJ, Xiong XS, Lü YQ, Fan R, Peng T. Effects of bilateral upper limb transcutaneous acupoint electrical stimulation on upper limb function in patients with subacute stroke and hemiplegia. *Chin J Rehab Theory Prac.* (2021) 27 (11):1318–22. doi: 10.1002/adhm.202100646

37. Zhang JJ, Xiao HB, Yang J, Chen RQ, Zhu ZJ, Wang LY, et al. Clinical observation of the efficacy of acupuncture combined with mirror therapy in the treatment of upper limb motor dysfunction in stroke patients. *J Anhui Univ Trad Chin Med.* (2024) 43(2):57–61. doi: 10.3969/j.issn.2095-7246.2024.02.014

38. Chen LX, Li CJ, Yang AR. Effect of retained needling in scalp acupuncture combined with mirror therapy on lower limb dysfunction and activities of daily living in stroke patients. *Modern J Integr Trad Chin Western Med.* (2022) 31 (7):929–32. doi: 10.3969/j.issn.1008-8849.2022.07.012

39. Li JM, Chen WR, Dang H, Li CX, Wu JM. Intervention of combined scalp acupuncture cluster needling and mirror therapy on upper limb muscle tone and event-related potentials in elderly patients with acute cerebral infarction and hemiplegia. *Chin J Gerontol.* (2022) 42(15):3641–5. doi: 10.3969/j.issn.1005-9202.2022.15.006

40. Wang XT, Hu Y, Zhang DN, Zhou Z, Zhu CT. Effect of combined scalp acupuncture and mirror therapy on upper limb motor function recovery in patients with cerebral infarction and hemiplegia. *J Trad Chin Med.* (2021) 27(12):93–6. doi: 10.13862/j.cnki.cn43-1446/r.2021.12.019

41. Wang AJ, Jin Y, Lin L, Fu TF. Effect of scalp acupuncture combined with mirror therapy on lower limb motor function in stroke patients. *Chin J Phys Med Rehabil.* (2022) 44(2):531–3. doi: 10.3760/cma.j.issn.0254-1424.2022.02.008

42. Ge S, Yin ZL, Meng ZX, Zhang XB, Huang LH, Zhang MJ. Effect of scalp acupuncture plus mirror therapy on lower limb motor function and walking ability in patients with ischemic stroke. *Shanghai J Acu-mox.* (2021) 40(6):647–9. doi: 10. 13460/j.issn.1005-0957.2021.06.0647

43. Pang L, Fu XX. Clinical observation of gait in patients with hemiplegia after stroke treated with combined scalp acupuncture and mirror therapy. *Shandong Med J.* (2022) 016:062. doi: 10.3969/j.issn.1002-266X.2022.16.018

44. Chen LX, Li CJ, Wang TT, Yang AR. Effects of scalp acupuncture combined with mirror therapy on motor function and living ability in patients with post-stroke lower-limb dysfunction. *Shanghai J Acu-mox.* (2021) 40(3):279–81. doi: 10.13460/j.issn. 1005-0957.2021.03.0279

45. He Q, Fan L, Zhu J, Lian TT. Effects of warm acupuncture combined with mirror therapy on functional recovery, homocysteine, and brain-derived neurotrophic factor in elderly patients with hemiplegia after cerebral infarction. *Hainan Med J.* (2023) 34 (7):929–31. doi: 10.3969/j.issn.1003-6350.2023.07.004

46. Gou PP, Wei XL, Pan HY. Observation of the efficacy of combined warm needling moxibustion and mirror therapy in the treatment of shoulder-hand syndrome after stroke in elderly patients. *Hainan Med J.* (2023) 34(11):1556–9. doi: 10.3969/j.issn.1003-6350.2023.11.007

47. Luo Q, Lü J. Effect of combined warm needling moxibustion and mirror therapy on limb function and balance ability in patients with hemiplegia after

stroke. Clin Med Res Prac. (2020) 5(29):3. doi: 10.19347/j.cnki.2096-1413. 202029051

48. Zhang YN, Zheng P, Yan X, Chen Y. Acupuncture at Baxie points combined with mirror therapy for upper limb and hand function in post-stroke hemiplegia: a clinical study. *Chin Rehabil Med.* (2021) 36(6):353–6. doi: 10.3870/zgkf.2021.06.008

49. Duan C, Li ZL, Xia WG, Zheng CJ, Zhang YP, Li SC. Effect of acupuncture combined with mirror therapy on upper limb motor function recovery after stroke. *Neural Inj Funct Reconstr.* (2020) 15(3):155–8. doi: 10.16780/j.cnki.sjssgncj.2020.03. 009

50. Zhang YN, Yan X, Gao WN, Zheng P. Effect of acupuncture combined with mirror therapy on upper limb motor function in early-stage stroke patients. *World Latest Med Inf.* (2020) 20(82):186–7. doi: 10.3969/j.issn.1671-3141.2020. 82.103

51. Xie JJ, Li JX, Sun Q, Ma YJ. Therapeutic observation of acupuncture plus mirror therapy for upper-limb dysfunction of post-stroke hemiplegia. *Shanghai J Acu-mox.* (2018) 37(5):494–8. doi: 10.13460/j.issn.1005-0957.2018.13. 0052

52. Zhenyu M, Meifei X, Xiaofeng Y. Clinical study on scalp acupuncture combined with mirror therapy for spastic paralysis of upper limbs due to stroke. *J New Chinese Med.* (2019) 51:182–5. doi: 10.13457/j.cnki.jncm.2019.01.048

53. Liu H. Efficacy of acupuncture combined with mirror therapy in the treatment of upper limb dysfunction in patients with hemiplegia after stroke. *Chin Med Eng.* (2019) 27(9):58–9.

54. Zhang N, Qie SY, Zheng GH, Gong WJ. Effect of acupuncture combined with mirror visual feedback training on upper limb function and daily living ability in patients with hemiplegia after stroke. *Shandong J Trad Chin Med.* (2021) 40 (2):157–61. doi: 10.16295/j.cnki.0257-358x.2021.02.009

55. Zhang XH, Liang JH, Huang RM, Zhu LY. Observation on the efficacy and nursing effect of combined acupuncture and mirror therapy on the recovery of lower limb function after stroke. *Sichuan J Trad Chin Med.* (2018) 36(3):208–10. doi: 10.3969/j.issn.1000-3649.2018.03.016

56. Yang Q, Ni L. Rehabilitation efficacy of combined acupuncture and mirror feedback therapy on lower limb spasticity in stroke patients. *World J Trad Chin Med.* (2020) 15(19):2983–7. doi: 10.3969/j.issn.1673-7202.2020.19.027

57. Tan Z, Li ZR, Tan ZC, Li XQ, Yu BL. Clinical observation of scalp acupuncture combined with mirror therapy in the treatment of unilateral neglect after stroke. *J Guangzhou Univ Trad Chin Med.* (2020) 37(12):2359–64. doi: 10.13359/j.cnki. gzxbtcm.2020.12.016

58. Shao-yang C, Ming-zhu X, Shu-hui W, Chun-zhi T, Xin-sheng L, Peng-dong J, et al. Effect of acupuncture plus mirror therapy on lower-limb dysfunction in

hemiplegia after cerebral infarction. Shanghai J Acu-Mox. (2017) 36:9–13. doi: 10. 13460/j.issn.1005-0957.2017.01.0009

59. Twitchell TE. The restoration of motor function following hemiplegia in man. Brain. (1951) 74(4):443-80. doi: 10.1093/brain/74.4.443

60. Krakauer JW. Motor learning: its relevance to stroke recovery and neurorehabilitation. *Curr Opin Neurol.* (2006) 19(1):84–90. doi: 10.1097/01.wco. 0000200544.29915.cc

61. Kwakkel G, Kollen BJ, van der Grond J, Prevo AJ. Probability of regaining dexterity in the flaccid upper limb: impact of severity of paresis and time since onset in acute stroke. *Stroke.* (2003) 34(9):2181–6. doi: 10.1161/01.STR.0000087172.16305.CD

62. Zhang D, Zou W, Zhang B, Guo P. Scalp acupuncture for post-stroke spastic hemiparesis: a systematic review and meta-analysis. *Medicine (Baltimore)*. (2024) 103(9):e37167. doi: 10.1097/MD.000000000037167

63. Zhang R, Lao L, Ren K, Berman BM. Mechanisms of acupunctureelectroacupuncture on persistent pain. *Anesthesiology*. (2014) 120(2):482-503. doi: 10.1097/ALN.00000000000101

64. Madhoun HY, Tan B, Feng Y, Zhou Y, Zhou C, Yu L. Task-based mirror therapy enhances the upper limb motor function in subacute stroke patients: a randomized control trial. *Eur J Phys Rehabil Med.* (2020) 56(3):265–71. doi: 10.23736/S1973-9087.20.06070-0

65. Yang Y, Wang Z, Hu Q, Long X, Ma G, Cui S, Xu M, Tang C, Yang C. The short-term effects of Jin's three needles in conjunction with mirror therapy on brain function in patients with upper limb disability following an ischemic stroke were evaluated using ReHo analysis. *Medicine (Baltimore)*. 2024 103(27):e38707. doi: 10.1097/MD.00000000038707

66. Bernhardt J, Hayward KS, Kwakkel G, Ward NS, Wolf SL, Borschmann K, et al. Agreed definitions and a shared vision for new standards in stroke recovery research: the stroke recovery and rehabilitation roundtable taskforce. *Int J Stroke.* (2017) 12 (5):444–50. doi: 10.1177/1747493017711816

67. Schwartz MH, Rozumalski A. The gait deviation index: a new comprehensive index of gait pathology. *Gait Posture*. (2008) 28(3):351–7. doi: 10.1016/j.gaitpost.2008.05.001

68. Bohannon RW. Hand-grip dynamometry predicts future outcomes in aging adults. J Geriatr Phys Ther. (2008) 31(1):3–10. doi: 10.1519/00139143-200831010-00002

69. Ward NS, Brown MM, Thompson AJ, Frackowiak RS. The influence of time after stroke on brain activations during a motor task. *Ann Neurol.* (2004) 55 (6):829–34. doi: 10.1002/ana.20099

70. Farina D, Merletti R, Enoka RM. The extraction of neural strategies from the surface EMG: an update. *J Appl Physiol.* (2014) 117(11):1215–30. doi: 10.1152/japplphysiol.00162.2014